Evidence map›Paper›PMID 23200938›Full record

ArticleVaccine2013

Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus.

Amy C Boyd, Raul Ruiz-Hernandez, Marylene Y Peroval, Connor Carson, Devanand Balkissoon, Karen Staines, Alison V Turner, Adrian V S Hill, Sarah C Gilbert, Colin Butter

Open access · hybridAbstract read
In one paragraph

Article in Vaccine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.

  1. Viral vector-based influenza vaccines.Human vaccines & immunotherapeutics · 2016
    Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. A review of H5Nx avian influenza viruses.Therapeutic advances in vaccines and immunotherapy · 2019
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Amy C BoydThe Jenner Institute, Oxford University, Oxford, UK.
Raul Ruiz-Hernandez
Marylene Y Peroval
Connor Carson
Devanand Balkissoon
Karen Staines
Alison V Turner
Adrian V S Hill
Sarah C Gilbert
Colin Butter
The Pirbright Institute · GBUniversity of Oxford · GBJenner Institute · GB

Funding

Biotechnology and Biological Sciences Research Council BB/E011691/1Biotechnology and Biological Sciences Research Council BBS/E/I/00001423Wellcome Trust 090532Wellcome Trust 095540
6 · The paper itself

Abstract

Current vaccines targeting surface proteins can drive antigenic variation resulting either in the emergence of more highly pathogenic viruses or of antigenically distinct viruses that escape control by vaccination and thereby persist in the host population. Influenza vaccines typically target the highly mutable surface proteins and do not provide protection against heterologous challenge. Vaccines which induce immune responses against conserved influenza epitopes may confer protection against heterologous challenge. We report here the results of vaccination with recombinant modified Vaccinia virus Ankara (MVA) and Adenovirus (Ad) expressing a fusion construct of nucleoprotein and matrix protein (NP+M1). Prime and boost vaccination regimes were trialled in different ages of chicken and were found to be safe and immunogenic. Interferon-γ (IFN-γ) ELISpot was used to assess the cellular immune response post secondary vaccination. In ovo Ad prime followed by a 4 week post hatch MVA boost was identified as the most immunogenic regime in one outbred and two inbred lines of chicken. Following vaccination, one inbred line (C15I) was challenged with low pathogenic avian influenza (LPAI) H7N7 (A/Turkey/England/1977). Birds receiving a primary vaccination with Ad-NP+M1 and a secondary vaccination with MVA-NP+M1 exhibited reduced cloacal shedding as measured by plaque assay at 7 days post infection compared with birds vaccinated with recombinant viruses containing irrelevant antigen. This preliminary indication of efficacy demonstrates proof of concept in birds; induction of T cell responses in chickens by viral vectors containing internal influenza antigens may be a productive strategy for the development of vaccines to induce heterologous protection against influenza in poultry.

Indexed as

Influenza VaccinesAdenoviridaeAnimalsChickensGenetic VectorsImmunization, SecondaryInfluenza A Virus, H7N7 SubtypeInfluenza in BirdsInterferon-gammaNucleocapsid ProteinsPoultryRecombinant ProteinsRNA-Binding ProteinsT-LymphocytesVaccinationVaccinia virusInfluenza VaccinesInterferon-gammaM1 protein, Influenza A virusNP protein, Influenza A virusNucleocapsid ProteinsRecombinant ProteinsRNA-Binding ProteinsViral Core ProteinsViral Matrix Proteins

Identifiers

PMID23200938
PMCPMC3605591
OpenAlexW1987580014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.